

Information Regarding Clinical Trial

Title	<p>A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Copanlisib in combination with Rituximab in patients with relapsed indolent B-Cell non-Hodgkins Lymphoma:</p> <p>Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma/Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma</p>
Protocol Number	<p>Chronos-3</p>
Sponsor	<p>Bayer</p>
Investigator	<p>Patrick M. Travis, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703</p>
Study Related Phone Numbers	<p>479-587-1700 (24 hours)</p>
Key Points for Study	<p>Histologically confirmed CD20 positive iNHL the 4 subtypes, must have relapsed after at least 1 prior line of therapy, including Rituxin. Ok to have previous P13K (except Copanlisib) provided no resistance, ECOG 2 or less, Life expectancy at least 3 mo, available fresh tissue or archival tissue at screening; See inclusion for non WM and WM.</p> <p>EXCLUSIONS: Progression free or treatment free interval of less than 12 mo since last Rituxin; for patients considered unfit for chemo interval is less than 6 mo since last Rituxin, CMV positive will not be eligible</p>